Finance

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">Boehringer Ingelheim, UCB venture arms seed hearing loss newco Rinri</h1><h2 class="title-bottom webtitle">Disease-modifying data convinced Boehringer Ingelheim Venture Fund to co-lead the seed round for U.K. stem cell hearing loss company Rinri </h2><div class="byline">Stephen Hansen, Associate Editor</div><div class="date"></div></div></div></div>

Boehringer Ingelheim Venture Fund

hearing loss

Marcelo Rivolta

Rinri Therapeutics Ltd.

UCB Ventures

Boehringer Ingelheim, UCB venture arms seed hearing loss newco Rinri

Disease-modifying data convinced Boehringer Ingelheim Venture Fund to co-lead the seed round for U.K. stem cell hearing loss company Rinri Therapeutics.

Disease-modifying data convinced Boehringer Ingelheim Venture Fund to co-lead the seed round for U.K. stem cell hearing loss company Rinri 

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>